Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 227

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 6
Chunk 227
---
 directors’ and officers’ insurance policy.
 
We have entered into agreements with each of our directors and executive officers. Each such agreement exculpates our director or officer, to the fullest extent permitted by law, from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them to the fullest extent permitted by law. This indemnification is limited to events determined as foreseeable by the board of directors based on our activities, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances.
 
The maximum indemnification amount set forth in such agreements is limited to an amount equal to 25% of our shareholders’ equity as reflected in our most recent consolidated financial statements prior to the date on which the indemnity payment is made. If the amount equal to 25% of our shareholders’ equity is insufficient to cover all indemnity amounts payable with respect to all indemnifiable directors and executive officers, such amount will be allocated among our directors and executive officers pro rata, in accordance with their relative culpabilities, as finally determined by a court with respect to a particular claim. The maximum amount set forth in such agreements is in addition to any amount paid (if paid) under insurance and/or by a third party pursuant to an indemnification arrangement. In the opinion of the SEC, indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.
 

D.          Employees
 
The total number of employees in Evogene and its subsidiaries as of December 31, 2022 ,2023 and 2024 was 137 ,142 and 117 respectively. As of December 31, 2024, our research and development activities involved 75 employees amounting to approximately 64% of our total full-time workforce, of which 36 were employed by Evogene and 39 were employed by our subsidiaries. In 2024, our employees included individuals with degrees in biology, chemistry, plant genetics, agronomics, computer and data science and other related fields and 36 of our employees hold a Ph.D. As of March 20, 2025, the total number of employees in Evogene and its subsidiaries was 106.
 
The rate of male v. female in our company and our main subsidiaries as of December 31, 2024, was as follows:
 

 Company      Female          Male         Total 
-------------------------------------------------
Evogene            56   %        44   %